Discovery of FOCAD: An Important Gene in Liver Cirrhosis

Conflict of Interest

None declared.

Author's Contribution

The author read and approved the final manuscript.

References

[1] Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS.Liver cirrhosis. Lancet 2021; 398(10308): 1359-1376

[2] Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M.Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 2021; 75(Suppl. 01): S49-S66

[3] Garrido A, Djouder N.Cirrhosis: a questioned risk factor for hepatocellular carcinoma. Trends Cancer 2021; 7(01): 29-36

[4] Baba MR, Buch SA.Revisiting cancer cachexia: pathogenesis, diagnosis, and current treatment approaches. Asia Pac J Oncol Nurs 2021; 8(05): 508-518

[5] Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK.The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery. J Hepatol 2021; 75(Suppl. 01): S118-S134

[6] Lim C, Turco C, Balci D.et al.Auxiliary liver transplantation for cirrhosis: from APOLT to RAPID: a scoping review. Ann Surg 2022; 275(03): 551-559

[7] Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S.Nonalcoholic steatohepatitis: a review. JAMA 2020; 323(12): 1175-1183

[8] Peng CY, Chien RN, Liaw YF.Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57(02): 442-450

[9] Traspas RM, Teoh TS, Wong PM.et al.Loss of FOCAD, operating via the SKI messenger RNA surveillance pathway, causes a pediatric syndrome with liver cirrhosis. Nat Genet 2022; 54(08): 1214-1226

[10] Brand F, Förster A, Christians A.et al.FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol 2020; 139(01): 175-192

[11] Brockschmidt A, Trost D, Peterziel H.et al.KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. Brain 2012; 135(Pt 4): 1027-1041

[12] Ambade A, Lowe P, Kodys K.et al.Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology 2019; 69(03): 1105-1121

[13] Lan T, Li C, Yang G.et al.Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2. Hepatology 2018; 68(03): 1070-1086

[14] Diao F.Single-cell landscape of liver cancer in response to immunotherapy. Asia Pac J Oncol Nurs 2021; 8(06): 591-593

[15] Tacke F.Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs 2018; 27(03): 301-311

[16] Ratziu V, Sanyal A, Harrison SA.et al.Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology 2020; 72(03): 892-905

RIGHTS & PERMISSIONS

Global Medical Genetics